Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 233 Show results per page	View Search Criteria \| Help With Results

Last Modified: 12/24/2008


1.		Phase II/III Randomized Study of Adjuvant Active Specific Immunotherapy with Autologous Tumor Cells and BCG plus CTX and Low-Dose IL-2 for Stage II/III Renal Cell Adenocarcinoma (Summary Last Modified 09/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				under 75								CNR-9505 EU-95023


2.		Phase II Chemotherapy with MTX/CF, Aminopterin or M-BACOD plus CTX or BCG Immunotherapy for Advanced non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				25 to 65								DFCI-75116


3.		Phase II-III Chemotherapy with ADR/VCR/ARA-C plus Immunotherapy with BCG and Irradiated Cells for Acute Myelogenous Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				under 60								EORTC-LAM-4

Last Modified: 9/1/1988


4.		Phase II/III Randomized Study of Surgery Followed by No Further Treatment vs BCG-Tumor Vaccine with vs without Cyclophosphamide in Patients with Totally Resectable Liver Metastases from Colorectal Carcinoma (Summary Last Modified 09/88)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 and over								MGH-CR1 NCI-V88-419A

Last Modified: 9/1/1988


5.		Phase II/III Randomized Study of Intra-arterial FUDR vs FUDR/BCG-Tumor Vaccine vs FUDR/BCG-Tumor Vaccine/Cyclophosphamide in Patients with Unresectable Liver Metastases from Colorectal Carcinoma (Summary Last Modified 09/88)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 and over								MGH-CR2 NCI-V88-419B

Last Modified: 9/1/1988


6.		Phase II/III Randomized Study of 5-FU vs 5-FU/BCG-Tumor Vaccine vs 5-FU/BCG-Tumor Vaccine/Cyclophosphamide Following Resection in Patients with Resectable Nonhepatic Metastases from Colorectal Carcinoma or with Resectable Recurrent Primary Tumor (Summary Last Modified 09/88)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 and over								MGH-CR3 NCI-V88-419C

Last Modified: 9/1/1988


7.		Phase II/III Randomized Study of 5-FU vs 5-FU/BCG-Tumor Vaccine vs 5-FU/BCG-Tumor Vaccine/Cyclophosphamide in Patients with Unresectable Metastases from Colorectal Carcinoma (Summary Last Modified 09/88)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 and over								MGH-CR4 NCI-V88-419D

Last Modified: 2/1/1990


8.		Phase II/III Randomized Study of Surgery Followed by No Further Treatment or BCG-Tumor Vaccine with vs without Cyclophosphamide in Patients with Stage B2 Colorectal Carcinoma Who May Have Had a Prior Cancer or Received Radiotherapy or Chemotherapy (Summary Last Modified 02/90)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 and over								MGH-CR5 NCI-V88-419E

Last Modified: 8/1/1990


9.		Phase II/III Randomized Study of Surgery Followed by No Further Treatment vs BCG-Tumor Vaccine with vs without Cyclophosphamide in Patients with Clinical Stage II (Pathologic Stage III) or Resectable Recurrent Melanoma (Summary Last Modified 08/90)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 and over								MGH-M1 NCI-V88-420A

Last Modified: 8/1/1990


10.		Phase II/III Randomized Study of Surgery Followed by No Further Treatment vs BCG-Tumor Vaccine with vs without Cyclophosphamide in Patients with Clinical Stage III (Pathologic Stage III/IV) Melanoma (Summary Last Modified 08/90)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 and over								MGH-M2 NCI-V88-420B

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute